Endoscopy Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, United States.
Front Immunol. 2023 Jun 9;14:1212692. doi: 10.3389/fimmu.2023.1212692. eCollection 2023.
Gastric cancer (GC) is among the deadliest diseases with countless incidences and deaths each year. (Hp) is the primary type of microbe that colonizes the stomach. In recent years, increasing evidence has demonstrated that Hp infection is one of the main risk factors for GC. Elucidating the molecular mechanism of how Hp leads to GC will not only benefit the treatment of GC, but also boost the development of therapeutics for other gastric disorders caused by Hp infection. In this study, we aimed to identify innate immunity-related genes in GC and investigate their potentials as prognostic markers and therapeutic targets for Hp-related GC.
Firstly, we analyzed the differentially expressed innate immunity-related genes in GC samples from the TCGA database. Then prognostic correlation analysis was carried out to explore the prognostic value of these candidate genes. By combing transcriptome data, somatic mutation data, and clinical data, co-expression analysis, functional enrichment analysis, tumor mutational burden analysis, and immune infiltration analysis were performed to reveal the pathological relevance of the candidate gene. Finally, ceRNA network was constructed to identify the genes and pathways for the regulation of the candidate gene.
We revealed that protein tyrosine phosphatase non-receptor type 20 (PTPN20) is a significant prognostic marker in Hp-related GC. Thus, PTPN20 levels have the potential to efficiently predict the survival of Hp-related GC patients. In addition, PTPN20 is associated with immune cell infiltration and tumor mutation burden in these GC patients. Moreover, we have also identified PTPN20-related genes, PTPN20 protein-protein interactions, and the PTPN20 ceRNA network.
Our data suggest that PTPN20 may have critical functions in Hp-related GC. Targeting PTPN20 may be a promising way to treat Hp-related GC.
胃癌（GC）是发病率和死亡率都极高的疾病之一。（Hp）是定植于胃的主要微生物类型。近年来，越来越多的证据表明 Hp 感染是 GC 的主要危险因素之一。阐明 Hp 导致 GC 的分子机制不仅有益于 GC 的治疗，还将促进治疗由 Hp 感染引起的其他胃部疾病的药物的发展。在这项研究中，我们旨在鉴定 GC 中与固有免疫相关的基因，并研究它们作为 Hp 相关 GC 的预后标志物和治疗靶点的潜力。
首先，我们分析了 TCGA 数据库中 GC 样本中差异表达的固有免疫相关基因。然后进行预后相关性分析，以探讨这些候选基因的预后价值。通过整合转录组数据、体细胞突变数据和临床数据，进行共表达分析、功能富集分析、肿瘤突变负荷分析和免疫浸润分析，以揭示候选基因的病理相关性。最后，构建 ceRNA 网络，以鉴定候选基因的调节基因和通路。
我们揭示了蛋白酪氨酸磷酸酶非受体型 20（PTPN20）是 Hp 相关 GC 的一个重要预后标志物。因此，PTPN20 水平有可能有效地预测 Hp 相关 GC 患者的生存情况。此外，PTPN20 与这些 GC 患者的免疫细胞浸润和肿瘤突变负荷相关。此外，我们还鉴定了 PTPN20 相关基因、PTPN20 蛋白-蛋白相互作用和 PTPN20 ceRNA 网络。
我们的数据表明，PTPN20 可能在 Hp 相关 GC 中具有关键功能。靶向 PTPN20 可能是治疗 Hp 相关 GC 的一种有前途的方法。
